Marshall Wace’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Marshall Wace’s Portfolio DMK Stock Details DMK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-634	Closed	-$31K	–	2166
2019 Q3	$31K	Buy	+634	New	+$45.5K	﹤0.01%	1563
2016 Q2	–	Sell	-5,560	Closed	-$2.39M	–	1216
2016 Q1	$2.39M	Sell	5,560 -1,399	-20%	-$500K	0.02%	524
2015 Q4	$2.63M	Hold	6,959	–	–	0.02%	505
2015 Q3	$1.92M	Hold	6,959	–	–	0.02%	466
2015 Q2	$2.05M	Hold	6,959	–	–	0.03%	475
2015 Q1	$1.92M	Buy	6,959 +3,959	+132%	+$1.71M	0.03%	473
2014 Q4	$1.3M	Buy	3,000 +1,981	+194%	+$629K	0.02%	532
2014 Q3	$334K	Buy	+1,019	New	+$299K	﹤0.01%	694

Other funds holding DMK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Level Four Advisory Services Dallas, Texas $3.54B AUM 37.12% 1-Year Est. Return

B. Riley Wealth Advisors Boca Raton, Florida $2.57B AUM 28.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Marshall Wace's DMK Position: Q4 2019 in Review

Marshall Wace sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q4 2019, closing a stake of 634 shares — an estimated $31K sold.

Marshall Wace first reported a position in DMK in Q3 2014 and held it in 8 quarters. The position peaked at $2.63M in Q4 2015. 38 funds tracked by Wall St. Rank hold DMK as of Q4 2019.

Marshall Wace reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q4 2019 after selling out during the quarter.
Marshall Wace sold 634 DMK Pharmaceuticals Corporation Common Stock shares in Q4 2019, an estimated $31K.
Marshall Wace first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q3 2014 and held it in 8 quarters.
Marshall Wace's DMK Pharmaceuticals Corporation Common Stock position peaked at $2.63M in Q4 2015.
38 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q4 2019.

Based on Marshall Wace's 13F filing for Q4 2019, filed 14 Feb 2020.